Ignite Creation Date:
2024-05-06 @ 7:31 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06031454
Status:
COMPLETED
Last Update Posted:
2024-04-16
First Post:
2023-09-04
Brief Title:
Drug-durg Interaction of LeritrelvirRAY1216 With Midazolam Omeprazole Rosuvastatin Verapamil and Rifampin
Sponsor:
Guangdong Raynovent Biotech Co Ltd
Organization:
Guangdong Raynovent Biotech Co Ltd
Study Overview
Official Title:
A Open-Label Two-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of Leritrelvir With Midazolam Omeprazole Rosuvastatin Verapamil and Rifampin in Healthy Participants
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The drug-drug interaction study had been designed to investigate the effect of Leritrelvir on the pharmacokinetics of Midazolam Omeprazole Rosuvastatin and the effect of Verapamil and Rifampin on the pharmacokinetics of Leritrelvir
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None